NEW YORK, Feb. 17, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Psychemedics Corporation (“Psychemedics”) (NASDAQ:PMD) between February 28, 2014 and January 30, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Daly v. Psychemedics Corporation, et al. (Case No. 1:17-cv-10186) in the USDC for the District of Massachusetts. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra/psychemedics-corporation
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, among other allegations, throughout the Class Period Psychemedics issued materially false and/or misleading statements and/or failed to disclose that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of this conduct.
On January 31, 2017, Psychemedics issued a press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and is liable for millions in losses.
Take Action: if you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 



